linjc16/ctgov huggingface dataset:
Assessment of Tremor Using SNUMAP Motion Sensing System

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to record and measure tremor using portable six-axis (tri-axial accelerometer and tri-axial gyroscope) motion sensing system.

Detailed Description
-----------------
SNUMAP system is portable, finger-worn, battery powered device that contains MEMS (micro-electro-mechanical system) hybrid motion sensor (three-axis accelerometer and three-axis gyroscope). The SNUMAP device consists of a wrist module and finger module, which attaches to an patients's finger and transmits three dimensional motions to a wrist module for storage and further analysis. The aims of this study is to assess tremor severity using tri-axial accelerometry and gyroscope to determine the reliability and the correlation with clinical measurements.

Official Title
-----------------
Quantitative Assessment of Tremor Using Portable Six-axis (Tri-axial Accelerometer and Tri-axial Gyroscope) Motion Sensing System

Conditions
-----------------
Tremor

Intervention / Treatment
-----------------
* Device: SNUMAP


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age: 20-80 years Patients with tremor (involuntary, rhythmic, oscillatory movement in one or more body part) Subject who signed an informed consent Exclusion Criteria: Pregnant or nursing woman. Comorbid neurologic illnesses that impact the ability to perform the study tasks. Subjects with medical condition that in the opinion of the investigator would affect his/her ability to participate in this study.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: SNUMAP assessment<br>Uses SNUMAP motion sensing system to quantify tremor symptom. | Device: SNUMAP<br>* Portable six-axis (tri-axial accelerometer and tri-axial gyroscope) motion sensing system<br>* Other names: Hybrid (accelerometer and gyroscope);|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 3-D Accelerometric and gyroscope variables measured | Correlation between SNUMAP motion sensing system symptom assessment and clinical tremor rating scale (TRS) scores | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Tremor, SNUMAP, accelerometry, gyroscope, clinical rating scale
Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to find out the genetic and biochemical makeup of your neuroblastic tumor, which influences its aggressiveness and the suitable therapy. These research studies include surface marker analysis, cytogenetics, cancer genes,genome sequencing, tumor growth-related genes and tumor growth in test tubes. Your blood, marrow, and hematopoietic stem cell samples will also be tested for tumors or leukemia cells, and your serum tested for anti-tumor antibodies.

Detailed Description
-----------------
To collect tumor, marrow specimens prospectively to study the molecular-genetic makeup of individual neuroblastic tumor and its metastasis by blood and marrow, and to correlate these findings with clinical outcome, and to relate the signaling circuitry of neuroblastic tumors to that of embryonic neuroectodermal cells. .

Official Title
-----------------
Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome

Conditions
-----------------
Neuroblastoma

Intervention / Treatment
-----------------
* Other: Tumor and Marrow Markers


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Neuroblastic tumors diagnosed in accordance with the International Neuroblastoma Staging System OR Clinically suspected neuroblastic tumors. PK DRAW INCLUSION CRITERIA (FOR PK DRAWS ONLY): PK Draw Inclusion Criteria Patients who receive naxitamab as part of their standard of care Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Tumor and Marrow Markers | Other: Tumor and Marrow Markers<br>* Tumor and Marrow Markers<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To study the molecular-genetic makeup and metastasis of neuroblastic tumors. | Before surgery a maximum of 5 blood drawings (20-30 ml) will be performed per year (at least one month apart) per patient | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To study the correlation of these biologic markers with clinical outcome. | Before surgery and a maximum of 5 blood drawings (20-30 ml) will be performed per year (at least one month apart) per patient | 2 years | 
| To relate neuroblastic tumor and embryonic neuroectodermal cell circuitry. | Up to six fetal adrenal samples will be obtained (without patient identifiers) from gestational week 20, when neuroblasts are present and thought to be differentiating within the fetal adrenal gland. | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Adrenal Gland, No stage requirement
Phase I Endovenous Administration of Oncolytic Adenovirus ICOVIR-5 in Patients With Advanced or Metastatic Melanoma

Study Overview
=================
Brief Summary
-----------------
The investigators will evaluate the safety of a single endovenous infusion of ICOVIR5 in adults with locally advanced and metastatic melanoma. ICOVIR5 consists in a conditionally replicative or oncolytic adenovirus.

Official Title
-----------------
Phase I Clinical Trial of Endovenous Administration of Conditionally Replicative Adenovirus ICOVIR-5 in Patients With Locally Advanced or Metastatic Melanoma

Conditions
-----------------
Locally Advanced or Metastatic Melanoma

Intervention / Treatment
-----------------
* Biological: ICOVIR-5


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Malignant melanoma advanced or metastatic. Other than 18 years Karnofsky index > 60 % Life expectancy > 3 months ALT/AST <=2.5 times the upper normal limit Creatinine clearance >= 50 ml/min. Bilirubin <25 umol/l Alkaline phosphatase <= 2.5 time upper normal limit Normal bone marrow function: Neutrophils >=1.5 E9/L, platelets >= 1E11/L, hemoglobin >= 100 g/l, Normal prothrombin time and thromboplastin time, HIV negative Measurable disease Signed informed consent. Exclusion Criteria: Geographical, social or psychological conditions that may impair the protocol compliance. Active infections or other severe medical status. History of liver disease. Other or concomitant treatments for melanoma or investigational product. Previous participation in studies with adenovirus. Virus diseases diagnosed two weeks before inclusion. Immunosuppressive concomitant treatments Concomitant malignant haematological disease. Patients having family members with immunodeficient status or disease Patients with Li Fraumeni syndrome or germinal retinoblastoma gene defects.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: ICOVIR5<br>ICOVIR-5 oncolytic adenovirus, single administration, endovenous, dose escalation from 1E11 vp to 1E13 vp. | Biological: ICOVIR-5<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Maximum tolerated dose | The highest dose where less than two out of three or six patients suffered dose limiting toxicity. | 4 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Recommended dose |  | 4 weeks | 
| Anti-tumour activity |  | 4 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
melanoma, oncolytic, adenovirus, virotherapy, locally advanced, metastatic
Genetic Registry for Rheumatoid Arthritis

Study Overview
=================
Brief Summary
-----------------
Many genes are thought to contribute to rheumatoid arthritis (RA). This study will attempt to identify genes that may contribute to RA.

Detailed Description
-----------------
The identification of genes for complex disorders such as RA requires large numbers of genetically informative families. This study enrolls people diagnosed with with RA and their families. This study will enroll 1000 RA patients and their parents. Participants with RA will be evaluated at his or her doctor's office or other location convenient for the participant. Participants will have a brief phone interview with a study coordinator and a blood sample will be obtained. Disease evaluation will be done at one visit and will include confirmation of diagnosis, a 28 joint count, joint alignment and mobility score (JAMS) and administration of a health assessment questionnaire.

Official Title
-----------------
Genetics of Rheumatoid Arthritis Registry

Conditions
-----------------
Rheumatoid Arthritis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult onset RA Diagnosis of RA made between 18 and 60 years old Both parents alive and willing to participate Parents may have diagnosis of RA (affected) or be unaffected Exclusion Criteria: Inflammatory bowel disease Lupus Psoriatic arthritis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Genetic Association with risk for rheumatoid arthritis | The project aims to identify risk alleles for rheumatoid arthritis using association methods in trio families, combined with data from singleton cases and multiplex families | 10 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Genetics
Arthroscopic Wafer and Ulnar Shortening in Ulnar Abutment

Study Overview
=================
Brief Summary
-----------------
there are many management options of ulnocarpal abutment depends on clinical evaluation and imaging of this joint. Arthroscopic treatment is the simplest solution for these conditions.

Official Title
-----------------
Comparative Study Between Arthroscopic Wafer and Ulnar Shortening Osteotomy in Ulnar Abutment Syndrome

Conditions
-----------------
Wrist Impaction

Intervention / Treatment
-----------------
* Procedure: wafer procedure
* Procedure: arthroscopy and ulnar shortening osteotomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: obvious ulnar abutment syndrome with ulnar side wrist pain Exclusion Criteria: ulnar minus or neutral variance central and radial wrist pain osteoarthritis of the wrist.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: group 1<br>wafer group procedure using an arthroscope through portal(radial to extensor carpi ulnaris, debridement of triangular fibro-cartilage complex 3-4 mm is shaved from the dome of the ulna by 2.9 bur. | Procedure: wafer procedure<br>* wrist arthroscopy and debridement of Triangular fibrocartilage and shortening of the head ulna by burr<br>|
| Active Comparator: group 2<br>ulnar shortening group :this is the most logical technique, dorsoulnar incision is made on the distal one-third of the forearm then a 6 hole 3.5 mm Dcp plate is position,osteotomy using oscillating saw in z-shaped manner. | Procedure: arthroscopy and ulnar shortening osteotomy<br>* wrist arthroscopy,debride debridement of Triangular fibrocartilage and shortening of the ulna by osteotomy and plate<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| mayo scoring system | follow up of the pain( nonpain,mild occasional, moderate and sever graded as 1,2,3,4 respectively | 6 month | 
| mayo scoring system | Range of motion of the wrist compared to the normal side(100 ,75-99,50-74,25-9,0-24% | 6 month | 
| mayo scoring system | grip strength | 6 month |
Effect of Resistance Training on Microvascular, Hemodynamic and Physical Parameters in Obese Adolescents

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate the effect os resistance training on microvascular reactivity, endothelial functions, inflammatory markers, blood pressure, heart rate, body composition and physical fitness in obese adolescents.

Official Title
-----------------
Effect of Resistance Training on Microvascular Reactivity, Endothelial Function, Inflammatory Markers, Body Composition, Blood Pressure, Heart Rate and Physical Fitness in Obese Adolescents

Conditions
-----------------
Obesity

Intervention / Treatment
-----------------
* Other: Resistance training


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Tanner pubertal stage of development between three and five age between 13 up to 17 years old Exclusion Criteria: presence of chronic diseases (diabetes mellitus, nephropathy and/or hypertension), musculoskeletal injury, smoking and to be in use of any medication.

Ages Eligible for Study
-----------------
Minimum Age: 13 Years
Maximum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Obese adolescents is being compared to control ones<br>Patients underwent to resistance training, three times a week, during three months. | Other: Resistance training<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Microvascular Reactivity |  | Three months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Endothelial function |  | Three months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Endothelial function, Microvascular reactivity, Obesity, Adolescents
AZD0530 Study 21 - Phase I Study in Patients With Solid Tumours

Study Overview
=================
Brief Summary
-----------------
This is a dose escalation study to assess the safety and tolerability of AZD0530 in patients with advanced solid malignancies.

Official Title
-----------------
A Phase I, Open-label, Dose-escalation Study to Assess the Safety and Tolerability of AZD0530 in Patients With Advanced Solid Malignancies

Conditions
-----------------
Solid Tumor

Intervention / Treatment
-----------------
* Drug: AZD0530


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histologically or cytologically confirmed advanced carcinoma / solid tumour of known primary site, which is refractory to standard therapies or for which no standard therapy exists World Health Organisation (WHO) performance status 0 to 2 Life expectancy of at least 12 weeks Exclusion Criteria: Inadequate bone marrow reserve Inadequate liver function, renal function or low hemoglobin Unresolved toxicity from anti-cancer therapy

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>AZD0530 | Drug: AZD0530<br>* oral, tablet, once daily, dose will be variable<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The primary objective of this study is to evaluate the safety and tolerability of AZD0530 in Japanese patients with advanced solid malignancies by assessment of AEs, vital signs, ECG, laboratory findings, thoracic imaging and pulmonary function test. |  | Assessed on an ongoing basis after starting daily dosing with AZD0530 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To determine the single and multiple dose PK of AZD0530 when administered orally to patients with advanced solid malignancies by assessment of Cmin, Cmax, tmax, Cssmax, Cssmin, AUC0-t, AUC0-24, AUC, AUCss0-24, CL/F, t1/2 and R |  | 1 blood sample before the single dose and 11 samples afterwards until up to 146 hours after dose.1 blood sample before the start of daily dosing of AZD0530. With a further 12 samples over the next 22 days. | 
| Tumor response |  | at entry and then 6 and 12 weeks after starting daily dosing of AZD0530. Assesments will then be made every 9 weeks. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Advanced carcinoma
The Use of Clear Aligners With Movement Enhancement Techniques

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to use clear aligners to measure tooth movement and length of treatment.

Detailed Description
-----------------
Orthodontic tooth movement is the result of a force applied to the crown of a tooth and the biological remodeling of the gum and bony tissues.

Official Title
-----------------
The Use of Clear Aligners With Movement Enhancement Techniques

Conditions
-----------------
Malocclusion

Intervention / Treatment
-----------------
* Device: Movement Enhancement Technique
* Device: Clear Aligner


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Require Orthodontic Treatment Have a permanent dentition No craniofacial anomaly present No past and present signs and symptoms of periodontal disease No significant medical history or medication that would adversely affect the development or structure of the teeth and jaws and any subsequent tooth movement No previous orthodontic or orthopaedic relapse No history of trauma, bruxism or parafunction 16- 46 years old, inclusive No skeletal jaw discrepancy Angle Class I or Class II molar and canine relationship Crowding of at least 4mm per arch No osteoporosis drugs Exclusion Criteria: Subjects who do not fulfill all inclusion criteria requirements

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 46 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Movement Enhancement Technique<br>Movement Enhancement Technique Clear Aligner | Device: Movement Enhancement Technique<br>* Conventional Orthodontic treatment<br>Device: Clear Aligner<br>* Orthodontic treatment with Clear Aligner<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tooth Movement Change | Participants will be followed for the duration of orthodontic treatment, an expected average of 78 weeks. Tooth movement change will be measured as the number of millimeters of tooth movement per aligner. | Baseline and end of treatment, an average of 78 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Length of Treatment Change | Participants will be followed for the duration of orthodontic treatment, an expected average of 78 weeks. Length of treatment change will be measured as the number of weeks of movement per aligner. | Baseline and end of treatment, an average of 78 weeks |